# **Special Issue**

# Strategies for Combatting Multidrug-Resistant and Extensively Drug-Resistant Bacteria: Current Challenges and Future Prospects

# Message from the Guest Editors

Antimicrobial resistance is currently considered one of the most important threats to global public health by the World Health Organization. Globally, multidrug-resistant (MDR) and extensively drug-resistant (EDR) bacterial pathogens are spreading. Although the acquisition of resistance is a natural process, the misuse of antibiotics, inadequate surveillance, and the poorly controlled regulation of antibiotics in clinical medicine and in the livestock industry potentiate the uprise and worldwide spread of MDR bacteria. We should focus on new strategies, including those that are not only related novel antimicrobial drugs but as well as those related to uncommon drug strategies such as use of bacteriophages, autovaccines, or personalized microbiota and antimicrobial stewardship with updated guidelines. We hope you find this topic exciting and will join our journey to find new and innovative strategies to decrease the mortality and morbidity of patients suffering from MDR and EDR pathogens.

#### **Guest Editors**

Dr. Adriána Liptáková

Institute of Microbiology, Faculty of Medicine, Comenius University, University Hospital Bratislava, 81108 Bratislava, Slovakia

Dr. Bożena Futoma-Kołoch

Department of Microbiology, University of Wroclaw, Wroclaw, Poland

## Deadline for manuscript submissions

closed (31 October 2023)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/142528

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



# **About the Journal**

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

#### Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

#### **Author Benefits**

## **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

